Contact us: +91 9550333722 040 - 40102781
Structured search
India
Choose your country
Different countries will display different contents
Try our best to find the right business for you.
My chemicalbook

Welcome back!

HomeProduct name listEptifibatide Acetate

Eptifibatide Acetate

Synonym(s):Cyclo(S,S)-Mpr(Har)GDWPC-NH2 acetate;N6-(Aminoiminomethyl)-N2-(3-mercapto-1-oxopropyl)-L-lysylglycyl-L-α-aspartyl-L-tryptophyl-L-prolyl-L-cysteinamide cyclic (16)-disulfide acetate

  • CAS NO.:148031-34-9
  • Empirical Formula: C35H49N11O9S2
  • Molecular Weight: 831.96
  • MDL number: MFCD05662245
  • EINECS: 1533716-785-6
  • SAFETY DATA SHEET (SDS)
  • Update Date: 2024-08-21 22:41:43
Eptifibatide Acetate Structural

What is Eptifibatide Acetate?

The Uses of Eptifibatide Acetate

The acetate salt form of eptifibatide (E592000), an arginine-glycine-aspartate-mimetic which reversibly binds to platelets to reduce the risk of cardiac ischemic events.

What are the applications of Application

Eptifibatide is a cyclic heptapeptide containing 6 amino acids and 1 mercaptopropionyl (des-amino cysteinyl) residue. An interchain disulfide bridge is formed between the cysteine amide and the mercaptopropionyl moieties. Chemically it is N6-(aminoiminomethyl)-N2-(3-mercapto-1-oxopropyl)-Llysylglycyl-L-α-aspartyl-L-tryptophyl-L-prolyl-L-cysteinamide, cyclic (1→6)-disulfide. Eptifibatide binds to the platelet receptor glycoprotein (GP) IIb/IIIa of human platelets and inhibits platelet aggregation.
The eptifibatide peptide is produced by solution-phase peptide synthesis, and is purified by preparative reverse-phase liquid chromatography and lyophilized. The structural formula is:

Structure of Eptifibatide

Indications

Acute Coronary Syndrome (ACS)
INTEGRILIN? is indicated to decrease the rate of a combined endpoint of death or new myocardial infarction (MI) in patients with ACS (unstable angina [UA]/non-ST-elevation myocardial infarction [NSTEMI]), including patients who are to be managed medically and those undergoing percutaneous coronary intervention (PCI).
Percutaneous Coronary Intervention (PCI)
INTEGRILIN is indicated to decrease the rate of a combined endpoint of death, new MI, or need for urgent intervention in patients undergoing PCI, including those undergoing intracoronary stenting.

Dosage forms

Before infusion of INTEGRILIN, the following laboratory tests should be performed to identify pre-existing hemostatic abnormalities: hematocrit or hemoglobin, platelet count, serum creatinine, and PT/aPTT. In patients undergoing PCI, the activated clotting time (ACT) should also be measured.
The activated partial thromboplastin time (aPTT) should be maintained between 50 and 70 seconds unless PCI is to be performed. In patients treated with heparin, bleeding can be minimized by close monitoring of the aPTT and ACT.

Properties of Eptifibatide Acetate

Melting point: >220°C (dec.)
storage temp.  Refrigerator
solubility  DMSO (Slightly), Methanol (Slightly), Water (Slightly)
form  Solid
color  White to Off-White
CAS DataBase Reference 148031-34-9(CAS DataBase Reference)

Safety information for Eptifibatide Acetate

Computed Descriptors for Eptifibatide Acetate

Related products of tetrahydrofuran

You may like

Statement: All products displayed on this website are only used for non medical purposes such as industrial applications or scientific research, and cannot be used for clinical diagnosis or treatment of humans or animals. They are not medicinal or edible.